Login or sign up
For business

Fulcrum Pharmaceuticals

3.9· 8 reviews
Average ratingAverage
3.9/ 5

Based on 8 reviews

525%
438%
338%
20%
10%
Ask AI

Ask Trustburn about Fulcrum Pharmaceuticals

Based on 8 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Dushyant Manhohan
Reviews 1

The service provided by this company was exceptional. I was impressed by the knowledge and professionalism of the staff. They provided me with accurate information and guidance throughout the process. The website was user-friendly and easy to navigate. Overall, I had a positive experience with this company.

John Lorton
Reviews 1

I had a great experience with Fulcrum Pharmaceuticals. The staff was very friendly and helpful. They answered all of my questions and made sure I understood everything. The website was easy to navigate and had all the information I needed. I would highly recommend Fulcrum Pharmaceuticals to anyone in need of their services.

John Sclapari
Reviews 1

Fulcrum Pharmaceuticals is a reputable company with a strong commitment to quality. I had a positive experience dealing with them. The staff was knowledgeable and friendly. The website is easy to navigate, and their products are of high quality. I would highly recommend Fulcrum Pharmaceuticals to others.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Fulcrum Pharmaceuticals

Fulcrum Pharmaceuticals applies computational chemistry, structural biology and thermodynamics to achieve accelerated design and development of drug products. Founded in 2002, Fulcrum has developed a portfolio of proprietary lead compounds targeted at inflammatory disease, osteoporosis, infectious disease and oncology. This portfolio includes small molecule inhibitors of receptors and enzymes, small molecule mimics of antibodies and receptors, and "adaptive" anti-infectives (drugs capable of overcoming resistance). Fulcrum's strategy is to out-license a portion of its pipeline, while retaining selected compounds for internal development. For more information, visit www.fulcrumpharmaceuticals.com.